IPO - Profile


We are an innovative biopharmaceutical company developing next-generation therapeutics based on our proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Our initial focus is on developing a novel class of T cell engagers (TCEs), and our lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors has faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$17.00 11,400,000 Positive High 20.9%

Offering Team

  • Legal counsel
  • Cooley LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 10 Jun, 2021

Offer 11 Jun, 2021

Look Ahead

Lock Up Expiry Dec 11, 2021

IPO Terms

Offer Price $17.00
Offer Size 11M

Market Sentiments

Stock Price